| DC Field | Value | Language |
|---|
| dc.contributor.author | Lucía Cabello-Alemán | - |
| dc.date.accessioned | 2023-04-11T11:47:12Z | - |
| dc.date.available | 2023-04-11T11:47:12Z | - |
| dc.date.issued | 2022 | - |
| dc.identifier.citation | Lucía Cabello-Alemán. Future directions in cancer immunotherapy with monoclonal antibodies / Lucía Cabello-Alemán ; Faculty of Sciences, University of Granada // Research Results in Pharmacology. - 2022. - Vol.8, №4.-P. 101-107. - Doi: 10.3897/rrpharmacology.8.85918. - Refer.: p. 105-107. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/52737 | - |
| dc.description.abstract | Cancer immunotherapy with monoclonal antibodies (mAbs) has become a therapy with great potential nowadays. It is based on the affinity of antibodies to bind to specific molecules, thus inhibiting the growth and spread of cancer. This mini-review will discuss the emerging alternatives of cancer immunotherapies based on mAbs | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | antibodies | ru |
| dc.subject | cancer | ru |
| dc.subject | disease | ru |
| dc.subject | emerging alternatives | ru |
| dc.subject | treatment | ru |
| dc.title | Future directions in cancer immunotherapy with monoclonal antibodies | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 8, № 4
|
